EP1720579A1 - Galactomannane et/ou glucomannane pour augmenter la disponibilite biologique d'agents actifs - Google Patents

Galactomannane et/ou glucomannane pour augmenter la disponibilite biologique d'agents actifs

Info

Publication number
EP1720579A1
EP1720579A1 EP05715350A EP05715350A EP1720579A1 EP 1720579 A1 EP1720579 A1 EP 1720579A1 EP 05715350 A EP05715350 A EP 05715350A EP 05715350 A EP05715350 A EP 05715350A EP 1720579 A1 EP1720579 A1 EP 1720579A1
Authority
EP
European Patent Office
Prior art keywords
vitamin
water
polysacchahd
group
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05715350A
Other languages
German (de)
English (en)
Inventor
Andreas Hefel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wheli Inter AG
Original Assignee
Wheli Inter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/780,152 external-priority patent/US20050181058A1/en
Priority claimed from DE102004008017A external-priority patent/DE102004008017A1/de
Application filed by Wheli Inter AG filed Critical Wheli Inter AG
Publication of EP1720579A1 publication Critical patent/EP1720579A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Definitions

  • US 4,675,312 discloses the production of polysaccharide agglomerates with the aim of enabling better intake by avoiding the other problems of galactomannan flour, such as viscosity and stickiness. 0
  • the production is carried out here by two different substances, namely one by the galactomannan and the other Second, through separate agglomeration formers. 5
  • the agglomeration agent is hardly restricted in the choice of available substances. It is only defined as a water supplier and can be of animal and / or vegetable origin.
  • the proportion of agglomeration agents in the total granulate is between 5 to 40%. Examples of such agglomeration formers are potatoes, milk and fruit.
  • US Pat. No. 4,675,312 accordingly describes the production of granules from galactomannans and associated agglomeration formers.
  • HGH growth hormone
  • the invention is therefore based on the object of further developing the preparation of polysaccharides, such as galactomannans and glucomannans, specified in US Pat. No. 4,675,312 so that they are also suitable for introducing active substances, such as human growth hormone, into human or animal metabolism ,
  • the invention is characterized by the technical teaching of claim 1.
  • the invention describes the possibility of individual compilation of the granules described with their effect on the human organism.
  • the invention thus has the following features: • Use of plant ingredients • Carrier by polysaccharides • Application in various areas (anti-aging, competitive sports) The active ingredients are embedded individually or as a complex separately in a plant matrix (polysaccharides / guar).
  • the advantage is the delayed , delayed release of the active substances into the blood, the exclusion of undesired interactions of different active substances with one another (antagonism) and the building up of large absorption surfaces in the small intestine.
  • the production of monopreparations and complexes as semi-finished preparations makes it possible to produce completely individual vital substance preparations for humans and animals in the simplest way.
  • L-methionine in the body converts it to cysteine, which is itself assembled into gluthathione.
  • L-glutathione (GSH) antioxidant antioxidant, antitoxin and enzyme cofactor.
  • GSH L-glutathione
  • An anti-degenerative, systemic protectorant An anti-degenerative, systemic protectorant.
  • NAC N-acetyl-L-cysteine
  • Arginine pyroglutamate triggers the secretion of growth hormones and increases the perception function.
  • NADH nicotinamide, adenine
  • ALA Alpha lipoic acid
  • Acetyl-L-carnitine reduces brain cell death.
  • Green tea extract is well known and has documented anti-aging effects.
  • Guar from guar gum galactomannan acts as a fiber and vegetable carrier matrix of the active ingredients.
  • Konjac from the Konjac plant glucomannan acts as a fiber and carrier matrix of the active ingredients.
  • Active ingredients can be vitamins, minerals, trace elements, plant ingredients, amino acids, coenzymes and other metabolically active substances in Table 1.
  • the invention is not limited solely to the active substances given in Table 1.
  • the active ingredient is dissolved in water or, in the case of fat-soluble active ingredients, it is suspended in water. This solution or suspension is slowly introduced into the purified polysaccharide and mixed. The resulting gel is dried using a gentle process in order not to destroy the sometimes sensitive active ingredients with temperature or oxygen. The cake resulting from the drying is crushed and sieved to the desired particle size (preferably 0.2 - 2 mm). The granulate obtained in this way has a residual moisture of about 5 - 7% and is therefore microbiologically stable.
  • the granulate When the granulate is ingested, it begins to swell and the embedded active ingredients are slowly released for absorption by the human or animal digestive system. A gel forms.
  • the high density of the polysaccharide matrix ensures that the swelling process only takes place in the interstinal tract. Water is continuously absorbed during the swelling process, thus loosening the matrix. In the course of this loosening, the embedded active ingredients can diffuse out of the matrix and thus be absorbed. The amount of active ingredient that is absorbed does not therefore exceed physiological concentrations, as can happen when a capsule or conventional dosage forms are released.
  • the continuous dissolution of the polysacccha gel through the digestive process causes the delayed release of the embedded active ingredients. This behavior largely corresponds to the natural conditions when taking vitamins or other active ingredients.
  • Fruit, vegetables, meat, and cereals are colloidal systems, as is the hydrocolloid galactomannan or glucomannan.
  • FIG. 1 Comparison of the kinetics of drug delivery in a conventional preparation compared to the drug when incorporated into a polysaccharide
  • FIG. 2 an enlarged, schematic representation of a granulate consisting of individual granulate particles
  • FIG. 3 an enlarged and schematic representation of a granulate particle with incorporation of HGH complexes
  • FIG. 4 a schematic illustration, which is enlarged still further compared to FIG. 3;
  • Figure 5 the functional kinetics of the molecular structure when water penetrates.
  • FIG. 1 shows a comparison of the active substance release in the human or animal body using two different active substance mechanisms.
  • the active substance concentration in the blood is shown on the ordinate, while the time is shown on the abscissa.
  • Curve Y shows a conventional transition of an active ingredient into the human or animal body. The result of this is that an approximately parabolic course is created, i. H. a very sharp increase in
  • curve Y compared to curve X thus shows that, thanks to the technical measures according to the invention, a high concentration of active substance in the blood can be achieved over a long period of time.
  • the graphic shows the possibility of a desired absorption delay by embedding the active ingredient in a polysacchahd. This means a more uniform supply and better use of the active ingredients in human and / or animal metabolism.
  • FIG. 2 shows an example of a granulate 1 which consists of a large number of granulate particles 2, 3.
  • the growth hormone HGH is embedded, as it is shown graphically as an HGH complex. This installation mechanism is mentioned in Example 3 of the above description.
  • the two granulate particles 2, 3 are completely functionally separated and do not mix or interact with one another in an undesirable manner. Because the active substances (ascorbic acid and selenite) are bound in different granulate particles 2, 3, an undesired interaction between these active substances in the gastrointestinal tract is prevented.
  • a granulate particle 3 With an enlarged, electron-microscopic representation of a granulate particle 3, it can be seen that it is formed from a multiplicity of reticulated or lattice-shaped polysaccharide molecules 5, which form a lattice structure 4.
  • the HGH complexes 7 are now integrated into the lattice structure 4 of the polysaccharide molecules 5 by means of a coordinative bond.
  • polysaccharide molecules 5 themselves are each surrounded by an illustrated HO shell which completely envelops and shields the thread-like structure.
  • the HGH complexes 7 are integrated in the space 6 between the molecules 5 due to the previously mentioned coordinative bond.
  • the HGH complexes are multivalued positive, while the OH group 8 carries a negative partial charge.
  • the HGH complexes are kept in the space 6 between the filiform polysaccharide ions due to the described coordinative bond.
  • the delayed release is justified by the fact that the individual threads are removed in layers by the penetrating water or the interstinal fluid and thus the lattice structure is also removed in layers so as to release the HGH complexes 7 stored in the interspace 6.
  • the galactomannan fibers are very closely connected in the dry flour. Mixing this network with water loosens these threads and surrounds them with the previously mentioned hydrate shell 9.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé pour augmenter la disponibilité biologique d'éléments nutritifs au moyen de polysaccharides tels que le galactomannane, le glucomannane et d'autres substances analogues pour faire passer des agents actifs comme, par exemple, l'hormone de croissance humaine HGH et d'autres dans le métabolisme humain ou animal. L'invention vise à perfectionner la production de polysaccharides tels que des galactomannanes et des glucomannanes pour les rendre aptes à faire passer des agents actifs comme l'hormone de croissance humaine dans le métabolisme humain ou animal.
EP05715350A 2004-02-17 2005-02-16 Galactomannane et/ou glucomannane pour augmenter la disponibilite biologique d'agents actifs Ceased EP1720579A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/780,152 US20050181058A1 (en) 2004-02-17 2004-02-17 Use of polysaccharides, such as galactomannans, glucomannans and the like for introducing active substances into the human or animal metabolism
DE102004008017A DE102004008017A1 (de) 2004-03-17 2004-03-17 Anwendung von Polysacchariden wie Galaktomannane, Glucomannane und dergleichen zur Einschleusung von Wirkstoffen, insbesondere dem menschlichen Wachstumshormons HGH in den menschlichen oder tierischen Stoffwechsel
PCT/EP2005/001546 WO2005079857A1 (fr) 2004-02-17 2005-02-16 Galactomannane et/ou glucomannane pour augmenter la disponibilite biologique d'agents actifs

Publications (1)

Publication Number Publication Date
EP1720579A1 true EP1720579A1 (fr) 2006-11-15

Family

ID=34888794

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05715350A Ceased EP1720579A1 (fr) 2004-02-17 2005-02-16 Galactomannane et/ou glucomannane pour augmenter la disponibilite biologique d'agents actifs

Country Status (3)

Country Link
EP (1) EP1720579A1 (fr)
JP (1) JP2007524690A (fr)
WO (1) WO2005079857A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637329A1 (fr) * 2006-02-01 2007-08-09 Nestec S.A. Systeme nutritionnel et procedes permettant d'augmenter la longevite
MY166532A (en) * 2006-02-10 2018-07-10 Mannatech Inc All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
US8491937B2 (en) * 2007-02-15 2013-07-23 Wyeth Llc Stability in vitamin and mineral supplements
RU2481351C2 (ru) * 2008-05-08 2013-05-10 Индус Биотек Прайвет Лимитед Композиции, содержащие галактоманнан, и способ их получения
ITRM20130655A1 (it) 2013-11-26 2015-05-27 Dicofarm Spa Prodotto a base di una associazione di glucomannano ed inositolo
CH710567A1 (de) * 2014-12-30 2016-06-30 Häcki Simone Haarwuchspräparat bzw. Nahrungsergänzungsmittel.
CN111728217A (zh) * 2020-07-07 2020-10-02 江西邦泰绿色生物合成生态产业园发展有限公司 一种玛咖纳豆制品复合制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652930A5 (de) * 1983-03-25 1985-12-13 Wheli Inter Ag Polysaccharid-agglomerat.
JPS6054321A (ja) * 1983-09-01 1985-03-28 Chiyoda Yakuhin Kk 粘度の安定なグルコマンナンとビタミンｃの健康食品用製剤
JPH04243819A (ja) * 1991-01-25 1992-08-31 Grelan Pharmaceut Co Ltd 徐放性製剤
DE4119306C2 (de) * 1991-06-12 1996-05-30 Wheli Inter Ag Organische Rohstoffe, Zwischen- und Endprodukte für die Ernährung und zur Verwendung für technische Zwecke, die Vitalstoffe enthalten
WO1997026865A1 (fr) * 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Excipient a liberation prolongee
JPH10114682A (ja) * 1996-10-11 1998-05-06 Shimizu Kagaku Kk グルコマンナン配合持効性内服用薬剤
EP0872233A1 (fr) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Médicaments antirétroviraux à biodisponibilité améliorée
ES2302881T3 (es) * 1997-07-29 2008-08-01 Alcon Laboratories, Inc. Composiciones oftalmicas que contienen polimeros de galactomanana y borato.
KR20000011247A (ko) * 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
CA2461708C (fr) * 2001-09-28 2012-08-07 Nutraceutix, Inc. Systeme de distribution de composant biologique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005079857A1 *

Also Published As

Publication number Publication date
WO2005079857A1 (fr) 2005-09-01
JP2007524690A (ja) 2007-08-30

Similar Documents

Publication Publication Date Title
DE69734841T2 (de) Zusammensetzungen auf pflanzlicher Kohlenhydratbasis als Nahrungsergänzungsstoffe
EP1720579A1 (fr) Galactomannane et/ou glucomannane pour augmenter la disponibilite biologique d'agents actifs
DE102008036954B4 (de) Verwendung einer Aminozucker enthaltenden Zusammensetzung
EP0434088B1 (fr) Compositions pharmaceutiques contenant de la L-carnitine
DE60207877T2 (de) Zusammensetzung enthaltend Procyanidine zur Verminderung des Appetits bei Säugetieren
EP1667665B1 (fr) Capsules comprenant pellets avec des agents actifs a liberation differentiee
DE202013002760U1 (de) Nahrungsergänzungsmittel zur medikationsorientierten Supplementierung
EP1330957B1 (fr) Complément alimentaire
DE102006056454A1 (de) Nahrungsergänzungsmittel
DE60224513T2 (de) Cactacea zubereitung mit fettbindenden eigenschaften, sowie verfahren ihrer herstellung
DE10221403A1 (de) Diätetische und pharmazeutische Zusammensetzungen, ihre Herstellung und ihre Verwendung
EP3357352B1 (fr) Composition comprenant des acides aminés
US20230355774A1 (en) Compositions containing coated minerals or mineral-amino acid complexes
EP1855653B1 (fr) Composition pour administration orale a liberation controlee de principes actifs
EP2648807B1 (fr) Préparation combinée destinée à améliorer la fertilité chez la femme
US20080206340A1 (en) Galactomannans and/or Glucomannans For Increasing the Bioavailability of Active Substances
US20050181058A1 (en) Use of polysaccharides, such as galactomannans, glucomannans and the like for introducing active substances into the human or animal metabolism
DE202004013660U1 (de) Vitamin-enthaltendes Produkt
DE202013002498U1 (de) Futtermittelzusatz für Nutz- und Haustiere
DE9412374U1 (de) Nahrungsergänzungsmittel
DE102006031441B4 (de) Orales Creatin-Supplement, sowie Verfahren zur Herstellung desselben
EP3387916B1 (fr) Composition comestible pour promotion digestiv
DE102020109099A1 (de) Ergänzungsfuttermittel für Schweine
DE60028132T2 (de) Neue verwendung von phospholiden pflanzlichen und tierischen ursprungs in nahrungstherapie
DE10339863A1 (de) Quellsubstratpellets als orale Darreichungsform für Ballaststoffe

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20061130

DAX Request for extension of the european patent (deleted)
APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120124